Medco, Molecular Targeting regulatory update

MRE received a worldwide license to Molecular Targeting’s Tc99m-Glucarate, a nuclear imaging agent for the early and rapid diagnosis of acute myocardial infarction. Molecular Targeting retains rights in Asia, excluding Japan. ...